drugset
drugset / Trial / NCT06908772

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

NCT06908772 ↗

Phase 2/3 Not yet recruiting 390 enrolled Shanghai JMT-Bio Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.

Timeline

Start
2025-04-01
Primary completion
2028-12-31
Completion
2030-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gumarontinib Small molecule 200 mg Oral
Subject Gumarontinib Small molecule 300 mg Oral
Subject Osimertinib Small molecule 80 mg Oral

Indications

No indication recorded.